Log in to search using one of your social media accounts:

This page shows you the latest items in this publication.

FDA approves first treatment for a form of Batten disease
The U.S. Food and Drug Administration today approved Brineura (cerliponase alfa) as a treatment for a specific form of Batten disease. Brineura is the first FDA-approved treatment to slow loss of walking ability (ambulation) in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase-1 (TPP1) deficiency. (Source: World Pharma News)
Source: World Pharma News - April 27, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

New data at AAN reinforce clinical benefit of Roche's OCREVUS ™ (ocrelizumab) for relapsing and primary progressive multiple sclerosis
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from the OCREVUS™ (ocrelizumab) clinical trial programmes will be presented during the 69th American Academy of Neurology (AAN) Annual Meeting in Boston, Massachusetts. The presentations will highlight new efficacy and safety analyses from the OCREVUS Phase II and Phase III trials, as well as from the open-label extensions. (Source: World Pharma News)
Source: World Pharma News - April 26, 2017 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Italian-style coffee reduces the risk of prostate cancer
Add another typical component of the Italian way of life to the long list of foods characterizing one of the most healthy populations in the world. This time it's coffee, prepared the Italian way. A research by the Department of Epidemiology and Prevention - I.R.C.C.S. Neuromed, Italy, in collaboration with the Italian National Institute of Health and the I.R.C.C.S. Istituto Dermopatico dell'Immacolata of Rome, shows that three or more cups a day can lower prostate cancer risk. (Source: World Pharma News)
Source: World Pharma News - April 26, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Merck divests Biosimilars business to Fresenius
Merck, a leading science and technology company, has announced the divestment of its Biosimilars business to Fresenius. The decision to divest Biosimilars is aligned with Merck’s strategy for its Healthcare business sector to focus on its pipeline of innovative medicines. (Source: World Pharma News)
Source: World Pharma News - April 25, 2017 Category: Pharmaceuticals Tags: Featured Merck Group Business and Industry Source Type: news

FDA takes action against 14 companies for selling illegal cancer treatments
The U.S. Food and Drug Administration today posted warning letters addressed to 14 U.S.-based companies illegally selling more than 65 products that fraudulently claim to prevent, diagnose, treat or cure cancer. The products are marketed and sold without FDA approval, most commonly on websites and social media platforms. (Source: World Pharma News)
Source: World Pharma News - April 25, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Novartis real-world data at AAN confirms benefit of Gilenya ® on four key measures of disease activity in relapsing MS
Novartis today announced data from the Phase IV Multiple Sclerosis and clinical outcome and MRI in the US (MS-MRIUS) study, which confirmed the effectiveness of Gilenya® (fingolimod) in the real-world setting, supporting previous findings from Phase III trials[1],[2]. (Source: World Pharma News)
Source: World Pharma News - April 24, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Research moves closer to unraveling mystery cause of multiple sclerosis
A new study has made a major new discovery towards finding the cause of multiple sclerosis (MS), potentially paving the way for research to investigate new treatments. Ahead of MS Awareness Week, which starts today, an international team involving the University of Exeter Medical School and the University of Alberta has discovered a new cellular mechanism - an underlying defect in brain cells - that may cause the disease, and a potential hallmark that may be a target for future treatment of the autoimmune disorder. (Source: World Pharma News)
Source: World Pharma News - April 24, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Pfizer unveils ATLAS ®, an interactive, user-friendly website that provides global antibiotic resistance surveillance data across 60 countries
Pfizer Inc. today announced the launch of the company's Antimicrobial Testing Leadership and Surveillance (ATLAS) website, which is designed to provide physicians and the global health community with easy access to critical data on the efficacy of various antibiotic treatments and emerging resistance patterns across more than 60 countries. (Source: World Pharma News)
Source: World Pharma News - April 21, 2017 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

When liver immune cells turn bad
A high-fat diet and obesity turn "hero" virus-fighting liver immune cells "rogue", leading to insulin resistance, a condition that often results in type 2 diabetes, according to research published today in Science Immunology. Using cells from mice and human livers, Toronto General Hospital Research Institute researchers demonstrated for the first time how under specific conditions, such as obesity, liver CD8+ T cells, white blood cells which play an important role in the control of viral infections, become highly activated and inflammatory, reprogramming themselves into disease-driving cells. (Source: World Pharma News)
Source: World Pharma News - April 21, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Merck partners with University of California, San Diego (UCSD) to fight Neglected Tropical Diseases
Merck, a leading science and technology company, today announced that it has agreed with the University of California, San Diego (UCSD) to share compounds under the WIPO Re:Search open innovation umbrella, thereby deepening its efforts in the fight against Neglected Tropical Diseases (NTDs) to identify potential cures for leishmaniasis, Chagas disease (American trypanosomiasis) and human African trypanosomiasis (HAT, sleeping sickness). (Source: World Pharma News)
Source: World Pharma News - April 20, 2017 Category: Pharmaceuticals Tags: Featured Merck Group Business and Industry Source Type: news

Lilly to present data for galcanezumab for the prevention of migraine at the American Academy of Neurology (AAN) annual meeting
Eli Lilly and Company (NYSE: LLY) will highlight Phase 2 data evaluating galcanezumab for the prevention of migraine at the American Academy of Neurology (AAN) annual meeting, which will take place April 22-28, 2017, in Boston. (Source: World Pharma News)
Source: World Pharma News - April 20, 2017 Category: Pharmaceuticals Tags: Featured Eli Lilly and Company Business and Industry Source Type: news

Fungi have enormous potential for new antibiotics
Fungi are a potential goldmine for the production of pharmaceuticals. This is shown by researchers at Chalmers University of Technology, who have developed a method for finding new antibiotics from nature's own resources. The findings - which could prove very useful in the battle against antibiotic resistance - were recently published in the journal, Nature Microbiology. (Source: World Pharma News)
Source: World Pharma News - April 19, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Oral contraceptives reduce general well-being in healthy women
One of the most common combined oral contraceptive pills has a negative impact on women's quality of life but does not increase depressive symptoms. This is shown by a major randomised, placebo-controlled study conducted by researchers at Karolinska Institutet in Sweden in collaboration with the Stockholm School of Economics. The results have been published in the scientific journal Fertility and Sterility. (Source: World Pharma News)
Source: World Pharma News - April 19, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Novartis expands development programs for NASH through clinical collaboration with Allergan
Novartis announced today that it has entered into a clinical trial agreement with Allergan plc to conduct a Phase IIb study, involving the combination of a Novartis FXR agonist and Allergan's cenicriviroc (CVC) for the treatment of non-alcoholic steatohepatitis (NASH). The financial details of this transaction are not disclosed. (Source: World Pharma News)
Source: World Pharma News - April 18, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Scientists discover how a decades-old drug reduces the size of a heart attack
Scientists at the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) have discovered a new mechanism of action of metoprolol, a drug that can reduce the damage produced during a heart attack if administered early. The team led by Dr. Borja Ibáñez, Clinical Research Director at the CNIC and cardiologist at the Fundación Jiménez Díaz University Hospital Health Research Institute (IIS-FJD), has identified the mechanism that explains why this drug is so beneficial: rapid administration of metoprolol during a heart attack directly inhibits the inflammatory action of neutrophils, a type of blood cell. (So...
Source: World Pharma News - April 18, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Bristol-Myers Squibb enters into separate agreements with Biogen and Roche to License anti-eTau and anti-myostatin compounds
Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has entered into two separate agreements to license BMS-986168, an anti-eTau compound in development for Progressive Supranuclear Palsy (PSP), to Biogen (NASDAQ:BIIB), and BMS-986089, an anti-myostatin adnectin in development for Duchenne Muscular Dystrophy (DMD), to Roche. (Source: World Pharma News)
Source: World Pharma News - April 13, 2017 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

Brain tissue from a petri dish
The most complex organ in humans is the brain. Due to its complexity and, of course, for ethical reasons, it is extremely difficult to do scientific experiments on it - ones that could help us to understand neurodegenerative diseases like Parkinson's, for example. Scientists at the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg have now succeeded in turning human stem cells derived from skin samples into tiny, three-dimensional, brain-like cultures that behave very similarly to cells in the human midbrain. (Source: World Pharma News)
Source: World Pharma News - April 13, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA approves first drug to treat tardive dyskinesia
The U.S. Food and Drug Administration approved Ingrezza (valbenazine) capsules to treat adults with tardive dyskinesia. This is the first drug approved by the FDA for this condition. Tardive dyskinesia is a neurological disorder characterized by repetitive involuntary movements, usually of the jaw, lips and tongue, such as grimacing, sticking out the tongue and smacking the lips. (Source: World Pharma News)
Source: World Pharma News - April 12, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

PatientsLikeMe and Shire Pharmaceuticals collaborate to study rare genetic diseases
PatientsLikeMe and Shire plc (LSE: SHP, NASDAQ: SHPG) have announced a new collaboration that will support the development of a patient-centered, real world health learning system that expands understanding of patient health and disease. Shire, the global leader in rare diseases and other highly specialized conditions, will work with PatientsLikeMe to appropriately engage patients and caregivers at every stage of their journey. (Source: World Pharma News)
Source: World Pharma News - April 11, 2017 Category: Pharmaceuticals Tags: Featured Shire Business and Industry Source Type: news

The accidental discovery of LSD
Bicycle Day on April 19 honors not the two-wheeled mode of transportation, but the colorful ride taken by Swiss chemist Albert Hoffman who accidentally discovered LSD 74 years ago. In search of new medicines, Hoffman was trying to stabilize lysergic acid, a derivative of a fungal compound used in a migraine medicine. He ended up synthesizing a compound called lysergic acid diethylamine, or LSD. Later, he accidentally exposed himself to it and felt dizzy with hallucinations. (Source: World Pharma News)
Source: World Pharma News - April 11, 2017 Category: Pharmaceuticals Tags: Featured Development Research and Development Source Type: news

Health risk assessments shed light on early predictors of depression
A new research study supported by Johnson & Johnson Health and Wellness Solutions suggests that health risk assessments (HRAs) can help predict depression in segments of the population who may not be routinely screened in traditional healthcare settings. HRAs are often used by employers and health plans to identify modifiable health risks, such as stress, sleep and quality of life. This new study demonstrates the value of HRAs to identify predictors for depression. (Source: World Pharma News)
Source: World Pharma News - April 11, 2017 Category: Pharmaceuticals Tags: Featured Johnson & Business and Industry Source Type: news

The first live-attenuated vaccine candidate completely protects against Zika infection
The first live-attenuated Zika vaccine still in the development stage completely protected mice against the virus after a single vaccination dose, according to new research from The University of Texas Medical Branch at Galveston and Instituto Evandro Chagas at the Ministry of Health in Brazil. The findings are currently available in Nature Medicine. (Source: World Pharma News)
Source: World Pharma News - April 10, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Phase III study shows Roche's Alecensa was superior to crizotinib in a specific type of lung cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the global, randomised phase III ALEX study met its primary endpoint and showed that Alecensa® (alectinib) as an initial (first-line) treatment significantly reduced the risk of disease worsening or death (progression-free survival, PFS) compared to crizotinib in people with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). (Source: World Pharma News)
Source: World Pharma News - April 10, 2017 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Towards a safe and scalable cell therapy for type 1 diabetes by simplifying beta cell differentiation
More than 36 million people globally are affected by type 1 diabetes (T1D), a lifelong disorder where insulin producing cells are attacked and destroyed by the immune system resulting in deficient insulin production that requires daily blood glucose monitoring and administration of insulin. While successful outcomes from islet transplantations have been reported, very few patients can benefit from this therapeutic option due to limited access to cadaveric donor islets. (Source: World Pharma News)
Source: World Pharma News - April 7, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Novartis to strengthen R & D pipeline by in-licensing ECF843 for ophthalmic indications
Novartis has exercised an option to in-license ECF843 for ophthalmic indications worldwide (outside Europe). The closing of the deal is subject to customary closing conditions including regulatory approvals. The financial and other terms of this transaction are not disclosed. ECF843 is a recombinant human lubricin (rh-Lubricin) protein, developed by Lubris LLC, Boston, USA. (Source: World Pharma News)
Source: World Pharma News - April 7, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

A one-two punch hits pancreatic cancer where it hurts
Australian scientists have uncovered a promising new approach to treating pancreatic cancer, by targeting the tissue around the tumour to make it 'softer' and more responsive to chemotherapy. The findings are published in Science Translational Medicine. In the study, which was carried out in mice and in patient-derived samples, researchers primed pancreatic tumours with a three-day course of Fasudil - a drug that 'slackens the ropes' of surrounding tissue to make tumours softer, and also makes the blood vessels around tumours 'leaky'. (Source: World Pharma News)
Source: World Pharma News - April 6, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA allows marketing of first direct-to-consumer tests that provide genetic risk information for certain conditions
The U.S. Food and Drug Administration today allowed marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions. These are the first direct-to-consumer (DTC) tests authorized by the FDA that provide information on an individual's genetic predisposition to certain medical diseases or conditions, which may help to make decisions about lifestyle choices or to inform discussions with a health care professional. (Source: World Pharma News)
Source: World Pharma News - April 6, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

First collaborative definition of patient centricity
AstraZeneca announced that BMJ Innovations has published the first collaborative definition of patient centricity for the pharmaceutical industry. The definition was co-developed with patients and caregivers using research led by AstraZeneca and patient community advocates to ensure a deep understanding of patient needs and values. Ten associated patient-centric principles were also identified and published in (Source: World Pharma News)
Source: World Pharma News - April 5, 2017 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Deep learning algorithm could boost drug development
Artificially intelligent algorithms can learn to identify amazingly subtle information, enabling them to distinguish between people in photos or to screen medical images as well as a doctor. But in most cases their ability to perform such feats relies on training that involves thousands to trillions of data points. This means artificial intelligence doesn't work all that well in situations where there is very little data, such as drug development. (Source: World Pharma News)
Source: World Pharma News - April 5, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Phase III ALUR study supports the use of Roche ’s Alecensa for people with advanced ALK-positive lung cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that the phase III ALUR study met its primary endpoint, demonstrating that Alecensa® (alectinib) significantly improved progression-free survival (PFS) in people with anaplastic lymphoma kinase (ALK)-positive advanced (metastatic) non-small cell lung cancer (NSCLC) who had progressed following treatment with one prior line of both platinum-based chemotherapy and crizotinib, compared with chemotherapy. (Source: World Pharma News)
Source: World Pharma News - April 4, 2017 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

New drug delivery system shows promise for fighting solid tumors
A new cancer-drug delivery system shows the ability to exploit the oxygen-poor areas of solid tumors that make the growths resistant to standard chemotherapy and radiation treatment. Carcinomas that affect the breast, lung, prostate and colon are among these solid-tumor cancers, as are malignancies in the lymphatic system, known as lymphomas, and the much less common sarcomas that arise in connective tissue. (Source: World Pharma News)
Source: World Pharma News - April 4, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Once-weekly semaglutide demonstrated consistent blood glucose reductions and weight loss regardless of background oral antidiabetic treatment
Findings from a post hoc analysis of the phase 3a SUSTAIN 2-4 trials demonstrated greater mean reductions in HbA1c and body weight with once-weekly semaglutide treatment compared to sitagliptin, exenatide extended release (ER) and insulin glargine U100 in adults with type 2 diabetes, across multiple background oral antidiabetic (OAD) treatment categories. (Source: World Pharma News)
Source: World Pharma News - April 3, 2017 Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news

The first overall survival data from the Phase 3 CheckMate -067 clinical trial
Bristol-Myers Squibb Company (NYSE:BMY) today announced the first overall survival (OS) data from the Phase 3 CheckMate -067 clinical trial. With a minimum follow-up of 28 months, the median OS had not yet been reached in either of the two Opdivo treatment groups and was 20 months for the Yervoy monotherapy group (95% CI: 17.1-24.6). Opdivo in combination with Yervoy and as a monotherapy reduced the risk of death 45% [hazard ratio (HR) 0.55; 95% CI: 0.42-0.72; P (Source: World Pharma News)
Source: World Pharma News - April 3, 2017 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

High doses of vitamin C to improve cancer treatment passes human safety trial
Clinical trials found that it is safe to regularly infuse brain and lung cancer patients with 800 - 1000 times the daily recommended amount of vitamin C as a potential strategy to improve outcomes of standard cancer treatments. In a work presented in Cancer Cell, University of Iowa researchers also show pathways by which altered iron metabolism in cancer cells, and not normal cells, lead to increased sensitivity to cancer cell death caused by high dose vitamin C. (Source: World Pharma News)
Source: World Pharma News - March 31, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Tagrisso (osimertinib) receives US FDA full approval
AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted full approval for Tagrisso (osimertinib) 80mg once-daily tablets, for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after an EGFR tyrosine kinase inhibitor (TKI) therapy. (Source: World Pharma News)
Source: World Pharma News - March 31, 2017 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Merck advances R & D strategy through unique development model with Avillion for Anti IL-17 A/F Nanobody
Merck, a leading science and technology company, today announced a development agreement with Avillion, a UK-based company focused on increasing R&D output through innovative models, for anti IL-17 A/F Nanobody®. Merck's Anti IL-17 A/F Nanobody® is an investigational therapy which has completed Phase I development, and is expected to begin Phase II in plaque psoriasis in 2017. (Source: World Pharma News)
Source: World Pharma News - March 30, 2017 Category: Pharmaceuticals Tags: Featured Merck Group Business and Industry Source Type: news

Anti-cancer drug gets a boost when combined with antirheumatic
Scientists at EPFL and NTU have discovered that combining an anticancer drug with an antirheumatic produces improved effects against tumors. The discovery opens a new path for drug-drug synergy. One of the goals in pharmacology is to increase the efficiency of drugs by minimizing their side effects. Recently, this effort has led to combining unrelated drugs to exploit their synergistic effects. (Source: World Pharma News)
Source: World Pharma News - March 30, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Daiichi Sankyo announces collaborative research on drugs for neglected tropical diseases
Daiichi Sankyo Company, Limited (Daiichi Sankyo), announced that it has entered into a new joint research agreement with the Drugs for Neglected Diseases initiative (DNDi) with regard to a new research program, the Hit-to-Lead Project, with the aim of developing drug treatments for two neglected tropical diseases (NTDs), leishmaniasis and Chagas disease. (Source: World Pharma News)
Source: World Pharma News - March 30, 2017 Category: Pharmaceuticals Tags: Featured Daiichi Sankyo Business and Industry Source Type: news

FDA approves Roche's OCREVUS ™ (ocrelizumab) for relapsing and primary progressive forms of multiple sclerosis
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved OCREVUS™ (ocrelizumab) as the first and only medicine for both relapsing and primary progressive forms of multiple sclerosis. The majority of people with MS have a relapsing form or primary progressive MS at diagnosis. (Source: World Pharma News)
Source: World Pharma News - March 29, 2017 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

How to get adults to eat their vegetables? Study explores potential of spices and herbs use
According to recent reports, most Americans, of all ages and genders, do not meet the recommended vegetable intake of 2 to 3.5 cups per day, consuming an average of only 1.5 cups per day. Although tactics such as providing vegetables as a juice or hidden as a puree in entrees have been suggested, many people still say no thanks to vegetables, citing adverse taste perception. (Source: World Pharma News)
Source: World Pharma News - March 29, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Neurological diseases cost the US nearly $800 billion per year
A new paper published in the Annals of Neurology reports the most common neurological diseases pose a serious annual financial burden for the nation. The report notes that the current estimated annual cost to American society of just nine of the most common neurological diseases is staggering, totaling $789 billion in 2014 dollars. These conditions include Alzheimer's disease and other dementias, low back pain, stroke, traumatic brain injury, migraine, epilepsy, multiple sclerosis, spinal cord injury, and Parkinson's disease. (Source: World Pharma News)
Source: World Pharma News - March 29, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA approves new eczema drug Dupixent
The U.S. Food and Drug Administration today approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis). Dupixent is intended for patients whose eczema is not controlled adequately by topical therapies, or those for whom topical therapies are not advisable. Dupixent can be used with or without topical corticosteroids. (Source: World Pharma News)
Source: World Pharma News - March 28, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb and the Cancer Research Institute announce collaboration to accelerate immuno-oncology research
The Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb Company (NYSE: BMY) and the Cancer Research Institute (CRI) today announced a multi-year clinical research collaboration to coordinate and rapidly initiate clinical Immuno-Oncology (I-O) studies across the Parker Institute and CRI networks. Bristol-Myers Squibb will work closely with leading Parker Institute and CRI scientists and researchers, (Source: World Pharma News)
Source: World Pharma News - March 28, 2017 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

Astrazeneca to share its robust early science in oncology with the medical community at AACR 2017
AstraZeneca, along with its global biologics research and development arm, MedImmune, will present the strength and depth of its translational science, which is expected to deliver the Company's next wave of innovative oncology medicines, at the American Association for Cancer Research (AACR) Annual Meeting in Washington DC, US, 1-5 April 2017. (Source: World Pharma News)
Source: World Pharma News - March 28, 2017 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Scientists discover mechanism that causes cancer cells to self-destruct
A new Tel Aviv University study published last month in Oncotarget discloses the role of three proteins in killing fast-duplicating cancer cells while they're dividing. The research, led by Prof. Malka Cohen-Armon of TAU's Sackler School of Medicine, finds that these proteins can be specifically modified during the division process - mitosis - to unleash an inherent "death mechanism" that self-eradicates duplicating cancer cells. (Source: World Pharma News)
Source: World Pharma News - March 27, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

XELJANZ ® (tofacitinib citrate) receives marketing authorisation in the European Union for the treatment of moderate to severe active rheumatoid arthritis
Pfizer Inc. (NYSE:PFE) announced today that the European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) oral tablets in combination with methotrexate (MTX) for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). (Source: World Pharma News)
Source: World Pharma News - March 27, 2017 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

TB Alliance sublicenses promising anti-tuberculosis drug from the Medicines Patent Pool
On World Tuberculosis Day, TB Alliance and the Medicines Patent Pool (MPP) announced a licensing agreement for the clinical development of sutezolid, an antibiotic drug candidate which demonstrated encouraging results in early studies. The sublicense pertains to the development of sutezolid in combination with other TB drugs and follows the MPP’s license for the treatment signed with patent holder The Johns Hopkins University in January. (Source: World Pharma News)
Source: World Pharma News - March 24, 2017 Category: Pharmaceuticals Tags: Featured Development Research and Development Source Type: news

FDA approves first treatment for rare form of skin cancer
The U.S. Food and Drug Administration has granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy. This is the first FDA-approved treatment for metastatic MCC, a rare, aggressive form of skin cancer. (Source: World Pharma News)
Source: World Pharma News - March 24, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Major breakthrough in the manufacture of red blood cells
Researchers have generated the first immortalised cell lines which allow more efficient manufacture of red blood cells. The team, from the University of Bristol and NHS Blood and Transplant, were able to manufacture red blood cells in a more efficient scale than was previously possible. The results, published in Nature Communications, could, if successfully tested in clinical trials, eventually lead to a safe source of transfusions for people with rare blood types, and in areas of the world where blood supplies are inadequate or unsafe. (Source: World Pharma News)
Source: World Pharma News - March 23, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Bayer's Rivaroxaban demonstrated superior protection against recurrent venous thromboembolism compared with Aspirin in EINSTEIN CHOICE study
Bayer AG and its development partner Janssen Pharmaceuticals, Inc. have announced results from the EINSTEIN CHOICE study, which demonstrated that both 10 mg and 20 mg once-daily dosages of its oral Factor Xa inhibitor rivaroxaban (Xarelto®) significantly reduced the risk of recurrent venous thromboembolism (VTE) compared with aspirin 100 mg once daily (acetylsalicylic acid, ASA) in patients who had previously completed 6 to 12 months of anticoagulation therapy for pulmonary embolism (PE) or symptomatic deep vein thrombosis (DVT). (Source: World Pharma News)
Source: World Pharma News - March 23, 2017 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news